Page 6 - Mapi Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

DUBAI, United Arab Emirates and NESS ZIONA, Israel, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd. (“Mapi” or the “Company”), a developer of...

ISRAEL21c compiles a list of the 10 most extraordinary medical devices and pharmaceuticals that promise to revolutionize global healthcare.

MRInsights.biz has rolled out a report titled Global Long-acting Injectable Medications Market Growth (Status and Outlook) 2021-2026 that is filled wi

5 (1) A Phase 3 trial investigating GA Depot, a long-acting, once-a-month injectable formulation of glatiramer acetate, is seeking patients with relapsing forms of multiple sclerosis (MS). Enrollment opened in 2019, with clinical sites in the U.S. and Eastern Europe added since then. More information on contacts and locations can be found here. People in the U.S. who are interested in participating can see if they are eligible here. GA Depot, developed by Mapi Pharma, is a new formulation of glatiramer acetate that lasts longer in the body and is administered via an intr...

ip eline drugs in the Primary Progressive Multiple Sclerosis pipeline landscapes. It comprises PPMS pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Primary Progressive Multiple Sclerosis therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive PPMS pipeline products.    Some of the crucial features of the Primary Progressive Multiple Sclerosis key players such as Atara Biotherapeutics, MediciNova, AB Science, and many others involved in targeted therapeutics development...